ClinicalTrials.gg
CompletedNCT02315443FRONTIERUpdated May 12, 2023

Field Randomization of Nerinetide (NA-1) Therapy in Early Responders

A Phase 3 interventional study of Nerinetide (NA-1) and Placebo in Acute Cerebral Ischemia, sponsored by NoNO Inc.. Completed at 4 sites in Canada. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2023-05-12.

Sponsored by NoNO Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
532
Allocation
Randomized
Ages
40 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 444 studies in Stroke with a site in Canada — 83 open to participants now, 99 under way, 13 of them phase 3. Stroke · Canada.

Enrollment
92nd of 374
532 · median 74
Started
2015
with 24 others
Phase 3
69 of 444
8 open now
Registered
182nd of 444
by date

Among the 444 studies in Stroke with a site in Canada, this one is the 92nd largest by enrollment of the 374 interventional ones that give a count, is one of 25 that started in 2015, is one of 69 in phase 3, and was the 182nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

83 of the 444 studies in Stroke with a site in Canada are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 40 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 444 studies in Stroke with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

Read the detailed description

Nerinetide (NA-1) is being developed as an emergency drug aimed at reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

The primary objective is to determine the efficacy of nerinetide in reducing global disability in patients with acute stroke. The secondary objectives are to determine the efficacy of nerinetide in reducing functional dependence, reducing mortality rate, reducing worsening of stroke, improving neurological outcome and improving activities of daily living.

The leading safety objectives are to determine the effect of administering a target dose of 2.60 mg/kg (up to a maximum dose of 270 mg) IV infusion of nerinetide within three hours of symptom onset by paramedics in the field on serious adverse events and 90-day mortality.

This trial is a multicenter, randomized, double-blind, placebo-controlled, single dose study initiated prehospital in the ambulance. It is being conducted using Emergency Medical Services (EMS) in Canada. Subjects with suspected acute stroke will be identified in the field by trained paramedics using the approved stroke protocol in use by the local EMS system, and further screened for eligibility and approval by an on-call trial physician. The paramedics will administer the study drug. Upon arrival at the emergency department, subjects will receive standard-of-care.

An Independent Data Monitoring Committee will perform safety reviews of the clinical data.

03

Conditions studied

  • Acute Cerebral Ischemia

Keywords

  • Stroke
  • Ischemia
  • Prehospital
  • NA-1
  • Modified Rankin Scale
  • Haemorrhagic stroke
  • Transient ischemic attack
  • Nerinetide
04

Who can participate

Ages eligible
40 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provisional diagnosis of acute stroke as identified by paramedics using the local stroke triage tool
  • Respiratory rate 12-24 breaths per minute
  • Oxygen saturation ≥ 90% on room air
  • Systolic blood pressure \< 90 or > 220 mmHg
  • Weight 45-120 kg
  • Last seen in usual state of health less than 3 hours before anticipated study drug initiation
  • Independently ambulatory with or without devices prior to event
  • LAMS score of 2-5 for at least 15 minutes and remains 2-5 at time of randomization

Exclusion criteria

Exclusion Criteria:

  • Lack of IV access
  • Canadian Triage and Acuity Scale Level 1 and/or uncorrected airway, breathing or significant circulatory problem
  • Blood sugar \< 3 mmol/L (\< 55 mg/dL)
  • Seizure at onset of symptoms or observed by paramedic
  • Glasgow coma score of \<10
  • Major head trauma in the last three months
  • Recent stroke in the last three months
  • Known or presumptive signs of pregnancy or breastfeeding
  • Prisoner
  • Long term care facility resident
  • Known advance directive to not resuscitate
  • Known participation in a clinical trial with an drug or device within 30 days preceding this trial
  • Pre-existing neurologic, psychiatric, or advanced systemic condition that would preclude obtaining the neurological or functional outcome evaluations
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
532 participants (actual)

Study arms

  • Experimental
    Nerinetide (NA-1)

    2.60 mg/kg of nerinetide (up to a maximum dose of 270 mg) administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.

    Drug: Nerinetide (NA-1)

  • Placebo comparator
    Placebo

    Placebo administered as a single 10 minute IV infusion using an ambulatory infusion pump early after stroke symptom onset.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Modified Rankin Scale (mRS) scale

    The percentage of responders, using a sliding dichotomy on the mRS

    Time frame: 90 days

Secondary outcomes

  1. mRS shift analysis

    Shift to reduced functional dependence analyzed across the whole distribution of scores on the mRS

    Time frame: 90 Days or the last rating

  2. Mortality rate

    A reduction in mortality as defined by event rate (proportion, expressed as a percentage)

    Time frame: 90 Days

  3. Worsening of stroke rate

    A reduction in proportion of participants with worsening of stroke. Worsening of stroke is defined as progression, or hemorrhagic transformation, of the index stroke as documented in the study CRF that (i) is deemed life-threatening and/or (ii) results in increased disability as gauged by a ≥4 point increase from lowest NIHSS during hospitalization and/or (iii) results in death.

    Time frame: 90 Days

  4. National Institutes of Health Stroke Scale (NIHSS)

    Proportion of subjects with good neurological outcome, as defined by a score of 0-1 on the NIHSS

    Time frame: 90 Days or the last rating

  5. Barthel Index

    Proportion of subjects with functional independence in activities of daily living, as defined by a score of ≥ 95 on the Barthel Index

    Time frame: 90 Days or the last rating

07

Study locations

4 sites
  • Kelowna General Hospital
    Kelowna, British Columbia V1Y 1T2, Canada
  • Royal Columbian Hospital
    New Westminster, British Columbia V3L 3W7, Canada
  • British Columbia Ambulance Service and British Columbia Emergency Health Services
    Vancouver, British Columbia V5M 4X6, Canada
  • Vancouver General Hospital, Vancouver Coastal Health
    Vancouver, British Columbia V5Z 1M9, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Mar 2023, 96 months.

Of 37 industry-sponsored phase 3 interventional studies under Stroke, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 96 months is above that.

Counting every sponsor, half of 130 studies reached it within 44 months; a quarter within 27 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2014
First posted
Dec 11, 2014
StartActual
Mar 26, 2015
Primary completionActual
Mar 27, 2023
CompletionActual
Mar 27, 2023
Last update
May 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02315443
Lead sponsor
NoNO Inc.
Collaborators
Brain Canada, Djavad Mowafaghian Centre for Brain Health, Canadian Stroke Network, University of Calgary, University of Toronto, University of British Columbia, Genome British Columbia
Responsible party
Sponsor
First posted
Dec 11, 2014
Start date
Mar 26, 2015
Primary completion
Mar 27, 2023
Completion
Mar 27, 2023
Last update
May 12, 2023

Study contacts

Jim Christenson, M.D.
principal investigator · University of British Columbia
Richard Swartz, M.D.
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerinetide

Start the discussion